Multimodal nutrition/anabolic therapy for wasting conditions

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 17, Issue 3, 2014, Pages 226-235

  Balstad, Trude Rakel ^a   Kaasa, Stein ^a,b   Solheim, Tora Skeidsvoll ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

anabolic; multimodal; nutrition; therapy; wasting

Indexed keywords

ANABOLIC AGENT; ANAMORELIN; ANDROGEN; CARNITINE; GHRELIN; ICOSAPENTAENOIC ACID; MEGESTROL ACETATE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELUMETINIB; ANDROGEN RECEPTOR;

CACHEXIA; DIET THERAPY; HORMONAL THERAPY; HUMAN; KINESIOTHERAPY; MUSCLE ATROPHY; MUSCLE MASS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; EXERCISE; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROCEDURES; WASTING SYNDROME;

ANABOLIC AGENTS; CACHEXIA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; EXERCISE; EXERCISE THERAPY; GHRELIN; HUMANS; NUTRITION THERAPY; RECEPTORS, ANDROGEN; WASTING SYNDROME;

EID: 84898541005     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000045     Document Type: Review

References (40)

1. Johns N, Stephens NA, Fearon KC. Muscle wasting in cancer. Int J Biochem Cell Biol 2013; 45:2215-2229.
2. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793-799.
3. von Haehling S, Steinbeck L, Doehner W, et al. Muscle wasting in heart failure: an overview. Int J Biochem Cell Biol 2013; 45:2257-2265.
4. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12:489-495.
5. Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia: pathophysiology and management. J Gastroenterol 2013; 48:574-594.
6. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 2012; 16:153-166.
7. Kraft M, Kraft K, Gartner S, et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN): a randomized multicentre trial. Nutr J 2012; 11:52.
8. Madeddu C, Dessi M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine celecoxib/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 2012; 31:176-182.
9. Argiles JM, Anguera A, Stemmler B. A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. Clin Nutr 2013; 32:319-324.
10. Prado CM, Bekaii-Saab T, Doyle LA, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 2012; 106:1583-1586.
11. Bekaii-Saab T, Phelps MA, Li X, et al. Multiinstitutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011; 29:2357-2363.
12. Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 2012; 31:765-773.
13. Sayer AA, Robinson SM, Patel HP, et al. New horizons in the pathogenesis, diagnosis and management of sarcopenia. Age Ageing 2013; 42:145-150.
14. Strasser B, Siebert U, Schobersberger W. Effects of resistance training on respiratory function in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Sleep Breath 2013; 17:217-226.
15. Stene GB, Helbostad JL, Balstad TR, et al. Effect of physical exercise on muscle mass and strength in cancer patients during treatment: a systematic review. Crit Rev Oncol Hematol 2013; 88:573-593.
16. Madeddu C, Maccio A, Mantovani G. Multitargeted treatment of cancer cachexia. Crit Rev Oncog 2012; 17:305-314.
17. Solheim TS, Laird BJ. Evidence base for multimodal therapy in cachexia. Curr Opin Support Palliat Care 2012; 6:424-431.
18. Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013; 14:335-345.
19. Papanicolaou DA, Ather SN, Zhu H, et al. A phase IIA randomized, placebocontrolled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging 2013; 17:533-543.
20. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21:129-137.
21. Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 2012; 118:4785-4794.
22. Miki K, Maekura R, Nagaya N, et al. Effects of ghrelin treatment on exercise capacity in underweight COPD patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment. BMC Pulm Med 2013; 13:37.
23. Miki K, Maekura R, Nagaya N, et al. Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS One 2012; 7:e35708.
24. Levinson B, Gertner J. Randomized study of the efficacy and safety of SUN11031 (synthetic human ghrelin) in cachexia associated with chronic obstructive pulmonary disease. e-SPEN J 2012; 7:e171-e175.
25. Pison CM, Cano NJ, Cherion C, et al. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial. Thorax 2011; 66:953-960.
26. DeBoer MD. Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes? Mol Cell Endocrinol 2011; 340:97-105.
27. Garin MC, Burns CM, Kaul S, Cappola AR. Clinical review: the human experience with ghrelin administration. J Clin Endocrinol Metab 2013; 98:1826-1837.
28. Argiles JM, Stemmler B. The potential of ghrelin in the treatment of cancer cachexia. Expert Opin Biol Ther 2013; 13:67-76.
29. Fearon KH. Selective androgen receptor modulators in cancer cachexia? Lancet Oncol 2013; 14:271-272.
30. Atlantis E, Fahey P, Cochrane B, et al. Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2013; 3:1- 14.
31. Churchward-Venne TA, Breen L, Phillips SM. Alterations in human muscle protein metabolism with aging: protein and exercise as countermeasures to offset sarcopenia. Biofactors 2013. [Epub ahead of print]
32. Dillon EL. Nutritionally essential amino acids and metabolic signaling in aging. Amino Acids 2013; 45:431-441.
33. Constantin D, Menon MK, Houchen-Wolloff L, et al. Skeletal muscle molecular responses to resistance training and dietary supplementation in COPD. Thorax 2013; 68:625-633.
34. Oldervoll LM, Loge JH, Lydersen S, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. Oncologist 2011; 16:1649-1657.
35. Breen L, Phillips SM. Nutrient interaction for optimal protein anabolism in resistance exercise. Curr Opin Clin Nutr Metab Care 2012; 15:226- 232.
36. Lundholm K, Daneryd P, Bosaeus I, et al. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function. Cancer 2004; 100:1967-1977.
37. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008; 24:305-313.
38. Anker MS, von Haehling S, Springer J, et al. Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Arch Med Sci 2013; 9:166-171.
39. Stewart Coats AJ, Srinivasan V, Surendran J, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV nonsmall cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle 2011; 2:201-207.
40. Prado CM, Sawyer MB, Ghosh S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 2013; 98:1012-1019.